We are live on ! Find out more
PM

Prosight Management Portfolio holdings

AUM $580M
1-Year Est. Return 29.81%
This Fund
S&P 500
This Quarter Est. Return
-1.07%
1 Year Est. Return
+29.81%
3 Year Est. Return
+39.55%
5 Year Est. Return
-6.93%
10 Year Est. Return
–
AUM
$210M
AUM Growth
-$22.7M
Cap. Flow
+$4.13M
Cap. Flow %
1.97%
Top 10 Hldgs %
48.59%
Holding
65
New
13
Increased
16
Reduced
18
Closed
18

Top Buys

Rank Stock Value
1
CUE icon
Cue Biopharma
CUE
+$7.68M
2
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$7.29M
3
BAX icon
Baxter International
BAX
+$6.69M
4
PRTA icon
Prothena Corp
PRTA
+$6.56M
5
MTCR
Metacrine, Inc. Common Stock
MTCR
+$5.31M

Top Sells

Rank Stock Value
1
KURA icon
Kura Oncology
KURA
+$12.8M
2
ARWR icon
Arrowhead Research
ARWR
+$4.93M
3
ARNA
Arena Pharmaceuticals Inc
ARNA
+$4.28M
4
ALDX icon
Aldeyra Therapeutics
ALDX
+$3.41M
5
VCEL icon
Vericel Corp
VCEL
+$2.9M

Sector Composition

Rank Sector Weight
1 Healthcare 92.06%
2 Technology 4.31%
3 Miscellaneous 3.63%
4 Energy 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALXN
1
DELISTED
Alexion Pharmaceuticals
ALXN
$13.3M 6.3%
115,800
+25,800
+29% +$2.78M
ARNA
2
DELISTED
Arena Pharmaceuticals Inc
ARNA
$12.2M 5.8%
163,057
-64,155
-28% -$4.28M
BMY icon
3
Bristol-Myers Squibb
BMY
$136B
$11.2M 5.32%
185,500
+67,500
+57% +$4.06M
RETA
4
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$11.2M 5.31%
114,554
+32,454
+40% +$4.06M
CUE icon
5
Cue Biopharma
CUE
$203M
$10.7M 5.08%
23,665
+13,322
+129% +$7.68M
BAX icon
6
Baxter International
BAX
$13.5B
$9.81M 4.67%
122,000
+79,500
+187% +$6.69M
CHNG
7
DELISTED
Change Healthcare Inc. Common Stock
CHNG
$9.06M 4.31%
624,200
-205,900
-25% -$2.62M
AUPH icon
8
Aurinia Pharmaceuticals
AUPH
$2.17B
$8.76M 4.17%
595,000
+503,000
+547% +$7.29M
ALDX icon
9
Aldeyra Therapeutics
ALDX
$89.9M
$8.09M 3.85%
1,092,000
-528,200
-33% -$3.41M
CI icon
10
Cigna
CI
$73.7B
$7.96M 3.79%
47,000
+8,500
+22% +$1.5M
EHC icon
11
Encompass Health
EHC
$11.9B
$7.01M 3.34%
135,657
+94,302
+228% +$4.84M
CNC icon
12
Centene
CNC
$32B
$6.88M 3.27%
117,935
-41,765
-26% -$2.59M
APTO
13
DELISTED
Aptose Biosciences, Inc.
APTO
$6.83M 3.25%
2,531
+791
+45% +$1.97M
ZBH icon
14
Zimmer Biomet
ZBH
$19.2B
$6.62M 3.15%
50,058
-20,497
-29% -$2.68M
QURE icon
15
uniQure
QURE
$3.38B
$6.31M 3%
171,429
+28,300
+20% +$1.16M
PRTA icon
16
Prothena Corp
PRTA
$479M
$5.45M 2.59%
+545,195
New +$6.56M
MTCR
17
DELISTED
Metacrine, Inc. Common Stock
MTCR
$5.3M 2.52%
+518,796
New +$5.31M
MGTX icon
18
MeiraGTx Holdings
MGTX
$1.33B
$5.18M 2.46%
391,099
-128,868
-25% -$1.7M
ACIU icon
19
AC Immune
ACIU
$263M
$4.5M 2.14%
923,117
-253,684
-22% -$1.82M
ALBO
20
DELISTED
Albireo Pharma Inc
ALBO
$4.09M 1.94%
122,500
-76,300
-38% -$2.22M
IOVA icon
21
Iovance Biotherapeutics
IOVA
$3.63B
$3.97M 1.89%
120,606
-94,394
-44% -$2.89M
ALXN
22
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
$3.89M 1.85%
+34,000
New +$3.67M
TBIO
23
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$3.84M 1.83%
282,100
+192,590
+215% +$2.97M
OEF icon
24
PUT
iShares S&P 100 ETF
OEF
$20.5B
$3.6M 1.71%
24,000
-171,000
-88% -$26.3M
CLLS
25
Cellectis
CLLS
$342M
$3.43M 1.63%
185,180
-91,397
-33% -$1.62M
1
2 3

Similar funds

SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
CCWM
Correct Capital Wealth Management Clayton, Missouri $580M AUM 16.45% 1-Year Est. Return
CMA
Cedar Mountain Advisors Lake Oswego, Oregon $581M AUM 18.16% 1-Year Est. Return
RIS
Retirement Income Solutions Ann Arbor, Michigan $581M AUM 19.42% 1-Year Est. Return
MFS
McNamara Financial Services Marshfield, Massachusetts $580M AUM 17.89% 1-Year Est. Return
GFI
Global Frontier Investments Charleston, South Carolina $581M AUM 8.55% 1-Year Est. Return
PWM
Praetorian Wealth Management Carmel, California $580M AUM 19.43% 1-Year Est. Return
CA
COFG Advisors Oak Brook, Illinois $579M AUM

Prosight Management's Q3 2020 Portfolio in Review

As of Q3 2020, Prosight Management held 65 positions worth $210M, down 9.8% from $233M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Prosight Management's Q3 2020 filing shows 13 new, 16 increased, 18 reduced and 18 closed positions. Its largest new stake was Prothena Corp: 545,195 shares worth $5.45M. The largest sale was Kura Oncology, an estimated $12.8M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 82% a quarter earlier, followed by Technology and Miscellaneous.

  • Prosight Management's largest Q3 2020 buy was Prothena Corp: 545,195 shares worth $5.45M.
  • Prosight Management added most to Cue Biopharma in Q3 2020, an estimated $7.68M increase.
  • Prosight Management's biggest Q3 2020 reduction was Kura Oncology, cutting an estimated $12.8M.
  • Prosight Management fully exited Arrowhead Research in Q3 2020, selling an estimated $4.93M.
  • Prosight Management's ten largest holdings make up 49% of its $210M portfolio in Q3 2020.
  • Prosight Management opened 13 new positions and closed 18 in Q3 2020.
  • Prosight Management's portfolio value fell 9.8% quarter-over-quarter to $210M.

Based on Prosight Management's 13F filing for Q3 2020, filed 13 Nov 2020.